India Releases Draft 2026 Pharmaceutical Patent Examination Guidelines Rebuilding Examiner Toolkit Around a Decade of Case Law

India's Controller General of Patents, Designs and Trade Marks (CGPDTM) published a Draft Guidelines document for the examination of pharmaceutical patent applications on September 4, 2026, inviting public comments before finalisation. The draft does not merely update the 2014 pharma guidelines; it rebuilds the examiner's toolkit around a decade of judicial development, spanning from the Supreme Court's 2013 Novartis查看公司主页 ruling to Delhi High Court decisions handed down as recently as July and September 2025 and 2026.

A Ground-Up Rebuild Around a Decade of Case Law

Pharmaceutical patenting occupies a uniquely contested space in Indian patent law. The Patents Act, 1970 was framed on the recommendations of the Bakshi Tek Chand and Ayyangar Committees precisely to prevent evergreening of drug monopolies, permitting only process patents for medicines until the TRIPS-driven amendments of 1999, 2002 and 2005 introduced product patents in a phased manner. Section 3(d), the mailbox mechanism, the Doha Declaration-inspired compulsory licensing provision (Section 92A), and the Biological Diversity Act's benefit-sharing regime all trace back to this history of balancing innovation incentives against public health access.

The 2014 Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals were the Patent Office's first dedicated attempt to bring consistency to this balancing act at the examiner's desk. Twelve years on, the courts have done much of the interpretive heavy lifting themselves. The Novartis查看公司主页, Cipla查看公司主页 v. Roche, Vifor v. MSN, Novozymes, Natco v. Novartis, DS Biopharma查看公司主页, Chinese University of Hong Kong, and the Sequenom-EMD Millipore-Natera trilogy of judgments (the last decided as recently as 9 October 2025) have each reshaped how novelty, inventive step, efficacy and method-of-treatment exclusions are actually applied.

Structure and the New Treatment of Markush Claims

The draft runs to thirteen substantive sections plus an Annexure, compared to the leaner ten-odd sections of the 2014 document. It opens with a detailed legislative history (Section 1), before moving through scope (Section 2), the relevant statutory provisions (Section 3), a new dedicated treatment of the types of claims filed in pharmaceutical applications including Markush claims (Section 4), prior art search methodology specific to chemical compounds (Section 5), the invention threshold under Section 2(1)(j) (Section 6), novelty (Section 7), inventive step (Section 8), industrial applicability (Section 9), the non-patentability exclusions under Section 3 (Section 10), sufficiency of disclosure, clarity and support (Section 11), and unity of invention (Section 12). Annexure I supplies a non-exhaustive list of roughly seventy worked illustrative examples — more than double the illustrative material found across the entire 2014 guidelines.

Section 4 is new in substance. It catalogues the categories of claims typically seen in pharma applications, including new chemical entities, formulations and combinations, the various "new forms" of known substances (salts, esters, ethers, polymorphs, solvates, stereoisomers, metabolites, pro-drugs, complexes), kits, product-by-process claims, process/manufacturing claims, use claims including second medical use, method-of-treatment claims, and selection inventions.

More significantly, it devotes sustained attention to Markush claims, which are near-ubiquitous in pharmaceutical drafting but received only passing mention in 2014. The draft directs examiners to check whether the specification discloses the best representatives of the claimed genus, whether those representatives share a common property and a common structural element, whether physical and chemical data and test results are provided for representatives, and whether at least one enabling process for the whole claimed scope is disclosed. Failure on any of these fronts can now trigger an explicit objection on unity of invention or sufficiency of disclosure.

Novelty: The "Seven Stambha" Approach

The most visible doctrinal import into the 2026 draft is the "Seven Stambha Approach" to novelty assessment, lifted directly from the Delhi High Court's decision in Telefonaktiebolaget LM Ericsson (Publ) v. Lava International Ltd. (decided 28 March 2024). "Stambha" means pillar, and the seven pillars require an examiner to: understand the claims, identify relevant prior art, analyse that prior art against the claims, determine whether disclosure is explicit or implicit, assess material differences across the whole scope of the claims, verify novelty in light of the claimed combination as a whole (not just individual elements), and document the reasoning behind the finding.

The draft also devotes a dedicated subsection to product-by-process claims, anchored in the Delhi High Court's 2024 ruling in Vifor (International) Ltd v. MSN Laboratories (搜索)搜索该词条, which held that the novelty of a product-by-process claim must be assessed on the novelty of the product itself, "shorn of the process terms." A worked example on fumarate salt disclosure by implication illustrates how far implicit disclosure now reaches in defeating novelty.

Inventive Step: Structured Tests with a Warning Against Rigid Formulas

On inventive step, the draft sets out both the four-step test from Lava International v. Ericsson and the five-step test from the Division Bench ruling in F. Hoffmann-La Roche (搜索)搜索该词条 Ltd. v. Cipla查看公司主页 Ltd. (2015), while explicitly cautioning, through the Delhi High Court's 2026 ruling in Sulzer Mixpac AG v. Assistant Controller of Patents, that these structured tests "cannot be regarded as commandments cast in stone." The draft also incorporates the ex-post facto analysis bar from Avery Dennison v. Controller of Patents and the September 2025 Delhi High Court ruling in Saint Gobain Glass France v. Assistant Controller of Patents, which confirms that mosaicing of prior art documents is permitted for inventive step (unlike novelty) so long as hindsight is excluded from the analysis.

Section 3(d): Efficacy After Novartis, Bioavailability After Natco

Section 3(d) receives the most extensive treatment of any single provision in the draft, running through the Supreme Court's foundational 2013 ruling in Novartis查看公司主页 AG v. Union of India (the "Gleevec查看药品详情" case), which confined "efficacy" in the pharmaceutical context to therapeutic efficacy and rejected bioavailability improvements as inherently sufficient. The draft then layers in the Delhi High Court's 2024 clarification in Natco Pharma查看公司主页 v. Novartis AG that bioavailability is "one of the pharmacokinetic parameters and not a direct measure of therapeutic efficacy," the Madras High Court's 2023 ruling in Novozymes v. Assistant Controller of Patents on enzyme variants (rejecting a fixed numerical threshold for "enhancement" in favour of a case-by-case "reasonable enhancement" standard), and the Delhi High Court's 2022 ruling in DS Biopharma查看公司主页 v. Controller of Patents requiring the Patent Office to identify the specific known substance against which a Section 3(d) objection is raised.

Annexure I works through roughly seventeen fact patterns covering salts, esters, ethers, polymorphs, metabolites, pure forms, isomers, complexes and deuterated analogues of known substances, in each case turning on whether comparative efficacy data was actually placed on record — reinforcing that Section 3(d) in 2026 remains a data-driven, not formulaic, inquiry.

Section 3(i): Method of Treatment and the October 2025 Trilogy

The draft's treatment of Section 3(i) draws heavily on the Madras High Court's 2023 decision in The Chinese University of Hong Kong v. Assistant Controller of Patents, which distinguished diagnostic processes carried out on the body from diagnostic products, kits and instruments (patentable), and held that a screening test capable of identifying a condition qualifies as diagnostic regardless of whether the subject is symptomatic or asymptomatic. The draft also incorporates the Delhi High Court's Sequenom, EMD Millipore and Natera judgments, all decided on 9 October 2025, which supply a detailed lexicon distinguishing "medicinal," "surgical," "curative," "prophylactic" and "diagnostic" processes (excluded) from the corresponding tools, kits, devices and product-by-process inventions (patentable).

For applicants, the practical takeaway is consistent: claim the diagnostic kit, the assay device, or the therapeutic composition, not the manner of administering, testing, or diagnosing.

Sufficiency, Support and Unity of Invention

Sections 11 and 12 tighten the requirements around Markush claim support, the mandatory disclosure of source and geographical origin for biological material under the Biological Diversity Act framework, and deposit obligations under the Budapest Treaty. On unity of invention, the draft imports the Delhi High Court's 2023 ruling in Syngenta (搜索)搜索该词条 Ltd v. Controller of Patents on divisional applications, and flags the newly introduced Rule 13(2A), which for the first time permits filing a divisional application out of an existing divisional application, provided it is filed before the parent divisional is granted.

Implications for Applicants

The Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026 read less like a revision of the 2014 document and more like a ground-up rebuild around a decade of case law that the 2014 guidelines could not have anticipated. For patent applicants and their counsel, the immediate implication is that Section 3(d) efficacy data, Markush claim support, and product-by-process novelty arguments will need to be considerably more rigorous and better evidenced than routine prosecution practice has assumed.

The guidelines remain in draft form and open to stakeholder comment. Any comments or suggestions on the Draft Guidelines for Examination of Pharmaceutical Applications must be sent to cgoffice.in@gov.in and llc-ipo@gov.in on or before September 19, 2026.